Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
Open Access
- 5 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (9) , e015302
Abstract
Background: Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordability of cardiovascular disease and hypertension medicines to identify areas for improvement in access to medication treatment. Methods and Results: We used the World Health Organization online repository of national essential medicines lists ( EML s) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest‐price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low‐ and lower‐middle‐income countries and 60% in high‐ and upper‐middle‐income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low‐ and lower‐middle‐income countries compared with high‐ and upper‐middle‐income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days’ wage for brand medicine and 1.8 days’ wage for generics. Affordability was lower in low‐ and lower‐middle‐income countries than high‐ and upper‐middle‐income countries for both brand and generic medications. Conclusions: The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low‐ and lower‐middle‐income countries.Keywords
This publication has 21 references indexed in Scilit:
- The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adultsThe Lancet, 2019
- Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional surveyThe Lancet, 2017
- Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study dataThe Lancet Public Health, 2017
- Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseasesPLOS ONE, 2017
- Global Disparities of Hypertension Prevalence and ControlCirculation, 2016
- Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Essential Medicines Are More Available than Other Medicines around the GlobePLOS ONE, 2014
- Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income CountriesJAMA, 2013
- Global Brief on Hypertension: Silent Killer, Global Public Health CrisisIndian Journal of Physical Medicine and Rehabilitation, 2013
- Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declarationThe Lancet, 2013